Purdue Files ANDA Amid Global Bankruptcy Settlement Bid
Company Seeking To Become ‘Public Health Company’
Purdue Pharma has taken a step in its bid to develop and market generic versions of treatments to reverse opioid overdose “at or below cost,” following its filing for bankruptcy.
You may also be interested in...
Trove Of Opioid Documents May Help Shape Public Health Policy
As sponsors and US FDA continue to face fallout, newly launched digital archive of industry documents from opioid litigation and settlements will be free public resource for those investigating activities that led to the opioid epidemic. It is modeled on the archive of tobacco industry documents, which has been the basis of about 1,000 scientific publications.
Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled
In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.
Deficient Aseptic Filling And Freeze Drying Hamstring Sandoz’s US Herceptin
Sandoz spoke to Generics Bulletin in the wake of confirming a recent complete response letter for its partnered biosimilar Herceptin candidate in the US.